RP-HPLC Method Development and Validation for Simultaneous Estimation of Amitriptyline and Frovatriptan in Bulk and Pharmaceutical Dosage Forms
DOI:
https://doi.org/10.66220/tcgvcq60Keywords:
RP-HPLC, Inertsil C18 column, Amitriptyline, Frovatriptan, Method validation, Simultaneous estimation, Pharmaceutical analysisAbstract
An easy, rapid, and reliable reverse phase high performance liquid chromatographic (RP-HPLC) approach was devised and validated for the simultaneous estimation of Amitriptyline and Frovatriptan in bulk and pharmaceutical dosage forms. Chromatographic separation was successfully attained through an Inertsil C18 column (4.6 × 150 mm, 5 µm) packed with chemically bonded porous silica particles as the stationary phase. The optimized mobile phase consisted of methanol and phosphate buffer (pH 3.0) in the ratio of 70:30 % v/v, delivered at a constant flow rate of 0.8 mL/min. Detection was carried out at 260 nm using a UV detector. The method demonstrated excellent linearity over the concentration range of 100–500 µg/mL for Amitriptyline and 1–5 µg/mL for Frovatriptan, using correlation values close to 0.999, indicating strong proportionality between concentration and peak area. Precision studies showed percentage comparative standard deviation ranges beneath 2%, confirming good repeatability and consistency. Accuracy was evaluated by recovery studies, and percentage recoveries were found within the acceptable range of 98–102% for both drugs. The limits of detection and quantification were within acceptable limits, reflecting adequate sensitivity of the developed method. All validation parameters complied with ICH and USP guidelines, confirming the specificity, accuracy, precision, linearity, and robustness of the approach. Consequently, the suggested RP-HPLC technique utilizing an Inertsil C18 column is appropriate for standard quality control assessment of Amitriptyline or Frovatriptan in pharmaceutical formulations with high reliability and reproducibility.
Downloads
References
1. Chidambaram SB, Anand N, Varma SR, Ramamurthy S, Vichitra C, Sharma A, et al. Superoxide dismutase and neurological disorders. Vol. 16, IBRO Neuroscience Reports. 2024;23:16:373-394. doi: 10.1016/j.ibneur.2023.11.007
2. Ullah H, Arbab S, Tian Y, Liu CQ, Chen Y, Qijie L, et al. The gut microbiota–brain axis in neurological disorder. Vol. 17, Frontiers in Neuroscience. 2023;4:17:1225875. doi: 10.3389/fnins.2023.1225875.
3. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. doi: 10.1111/head.12499.
4. Sanford M. Frovatriptan: A review of its use in the acute treatment of migraine. Vol. 26, CNS Drugs. 2012; 1;26(9):791-811. doi: 10.2165/11209380-000000000-00000
5. Buchan P, Wade A, Ward C, Oliver SD, Stewart AJ, Freestone S. Frovatriptan: A review of drug-drug interactions. Vol. 42, Headache. 2002; 2:S63-73. doi; 10.1046/j.1526-4610.42.s2.4.x
6. Ramachandran R. Neurogenic inflammation and its role in migraine. Vol. 40, Seminars in Immunopathology. 2018; 40(3):301-314. doi: 10.1007/s00281-018-0676-y.
7. Conti P, D’Ovidio C, Conti C, Gallenga CE, Lauritano D, Caraffa A, et al. Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Vol. 844, European Journal of Pharmacology. 2019; 5:844:87-94. doi: 10.1016/j.ejphar.2018.12.004.
8. Brandes J, Poole A, Kallela M, Schreiber C, MacGregor E, Silberstein S, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133–48. doi: 10.1111/j.1468-2982.2009.01840.x.
9. Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Vol. 57, Headache. 2017; 57(2):194-208. doi: 10.1111/head.12978.
10. Ecks S. Where old is gold again: antidepressants in Nepal, 1961–2021. Biosocieties. 2022;17(4):601–18. doi: 10.1057/s41292-021-00233-9
11. McClure EW, Daniels RN. Classics in Chemical Neuroscience: Amitriptyline. Vol. 12, ACS Chemical Neuroscience. 2021; 3;12(3):354-362. doi: 10.1021/acschemneuro.0c00467.
12. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48(2):252–63. doi: 10.1016/j.neuropharm.2004.09.012.
13. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain-clinical and experimental studies. Pharmacol Reports. 2013;65(6):1611–21. doi: 10.1016/s1734-1140(13)71522-6.
14. Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, et al. Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics. 2018;28(7):179–87. doi: 10.1097/FPC.0000000000000341.
15. Reis H, Guatimosim C, Paquet M, Santos M, Ribeiro F, Kummer A, et al. Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes. Curr Med Chem. 2009;16(7):796–840. doi: 10.2174/092986709787549271.
16. Abo-Elghiet F, Elosaily H, Hussein DK, El-Shiekh RA, A’aqoulah A, Yousef EM, et al. Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications. Vol. 18, Pharmaceuticals. 2025; 22;18(2):139. doi: 10.3390/ph18020139.
17. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. Vol. 397, The Lancet. 2021; 17;397(10283):1505-1518. doi: 10.1016/S0140-6736(20)32342-4.
18. Thejaswini JC, Gurupadayya B, Professor A. Rp-Hplc Method Development and Validation for Simultaneous Determination of Amitriptyline, Carbamazepine and Flunarizine in Human Plasma Using Mitrazapin As Internal Standard. Indo Am J Pharm Res. 2014;4(8). doi: 10.1044/1980-iajpr.14322.
19. Shaikh S, Jain V. Development and validation of novel RP-HPLC method for simultaneous estimation of gabapentin and amitriptyline hydrochloride in bulk and pharmaceutical dosage forms. Int J Appl Pharm. 2018;10(2):97–104. doi: 10.22159/ijap.2018v10i2.24842.
20. Khalid M, Ahmad S. Box–Behnken Design Used to Optimize the Simultaneous Quantification of Amitriptyline and Propranolol in Tablet Dosages by RP-HPLC-DAD Method and Their Stability Tests. Separations. 2022;9(12). doi: 10.3390/separations9120421.
21. Pavan Kumar V, Ramadevi B, Karishma S, Divya P, Sivagami B, Niranjan M. Development and validation of new analytical method for the simultaneous estimation of amitriptyline and perphenazine in bulk and pharmaceutical dosage form by RP-HPLC. Int J Res Pharm Sci Technol. 2018;1(1):12–21. doi: 10.33974/ijrpst.v1i1.19
Downloads
Published
Data Availability Statement
All the data reported in this manuscript were generated and analysed using standardised and validated experimental methods.
Issue
Section
License
Copyright (c) 2026 Nampelly Karnakar, Ramana Hechhu, Sajja Ravindra Babu (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to the Journal of PharmTechNova (JPTN) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JPTN are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in the Journal of PharmTechNova (JPTN) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.
